Anika Therapeutics (NASDAQ:ANIK – Get Free Report) and Creative Medical Technology (NASDAQ:CELZ – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability.
Volatility and Risk
Anika Therapeutics has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. Comparatively, Creative Medical Technology has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings for Anika Therapeutics and Creative Medical Technology, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anika Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| Creative Medical Technology | 1 | 0 | 1 | 0 | 2.00 |
Anika Therapeutics currently has a consensus price target of $22.00, suggesting a potential upside of 13.11%. Given Anika Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Anika Therapeutics is more favorable than Creative Medical Technology.
Earnings and Valuation
This table compares Anika Therapeutics and Creative Medical Technology”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anika Therapeutics | $112.82 million | 2.31 | -$10.88 million | ($0.27) | -72.04 |
| Creative Medical Technology | $10,000.00 | 443.84 | -$5.99 million | ($2.07) | -0.33 |
Creative Medical Technology has lower revenue, but higher earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
91.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are held by institutional investors. 12.1% of Anika Therapeutics shares are held by company insiders. Comparatively, 1.0% of Creative Medical Technology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Anika Therapeutics and Creative Medical Technology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Anika Therapeutics | -3.14% | 0.20% | 0.15% |
| Creative Medical Technology | N/A | -86.52% | -81.96% |
Summary
Anika Therapeutics beats Creative Medical Technology on 9 of the 13 factors compared between the two stocks.
About Anika Therapeutics
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company’s joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
About Creative Medical Technology
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
